<DOC>
	<DOCNO>NCT00651183</DOCNO>
	<brief_summary>The objective PMS study evaluation depressive symptom measure Unified Parkinson 's Disease Rating Scale ( UPDRS ) Part I ( mentation , behavior mood ) Hospital Anxiety Depression Scale Depression Subscore ( HADS-D ) pramipexole treatment early advance PD patient . In addition investigate whether improvement depressive symptom link improvement motor function ( UPDRS Part III ) . 250 patient diagnose Parkinson 's disease ( PD ) investigate 80 specialist ( neurologist neurologists/psychiatrists ) across Austria . Pramipexole take orally initial dosage 0.375 mg/day ( use three time daily schedule independently food intake ) titrate upwards , require , weekly interval maximum total daily dose 4,5 mg ( TID ) per Summary Product Characteristics ( SPC ) .</brief_summary>
	<brief_title>Non-motor Symptoms ( Depressive Symptoms ) Parkinson 's Disease Their Course Under Pramipexole Treatment</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Idiopathic PD without fluctuation Indication treatment Pramipexole Presence least mild depressive symptom ( judged treat physician ) Ability reliably complete selfrating scale ( Hospital Anxiety Depression Scale ( HADS ) ) Any contraindication accord Summary Product Characteristics ( SPC ) , hypersensitivity pramipexole excipients Ongoing treatment pramipexole</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>